Show simple item record

dc.contributor.authorBunchman, Timothy E.en_US
dc.contributor.authorSedman, Aileen B.en_US
dc.contributor.authorKershaw, David B.en_US
dc.date.accessioned2006-09-11T19:26:52Z
dc.date.available2006-09-11T19:26:52Z
dc.date.issued1995-06en_US
dc.identifier.citationSedman, Aileen B.; Kershaw, David B.; Bunchman, Timothy E.; (1995). "Invited Review Recognition and management of angiotensin converting enzyme inhibitor fetopathy." Pediatric Nephrology 9(3): 382-385. <http://hdl.handle.net/2027.42/47835>en_US
dc.identifier.issn0931-041Xen_US
dc.identifier.issn1432-198Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/47835
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=7632538&dopt=citationen_US
dc.description.abstractAngiotensin converting enzyme (ACE) inhibitors are extensively used for the treatment of hypertension, to decrease proteinuria, and to mitigate hyperfiltration. These drugs now have been shown to be fetotoxic causing profound fetal hypotension, renal tubular dysplasia, anuria-oligohydramnios, growth restriction, hypocalvaria, and death when used in the second and third trimesters of pregnancy. We recommend that ACE inhibitors not be used in pregnancy. However, if a child is born with ACE inhibitor fetopathy, aggressive therapy with dialysis to remove the inhibitor may mitigate the profound hypotensive effects. Therapy will depend on the specific ACE inhibitor, and care recommendations cannot be generalized for the entire class of drugs as their protein binding and volume of distribution differ substantially.en_US
dc.format.extent421573 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherSpringer-Verlag; IPNAen_US
dc.subject.otherTherapyen_US
dc.subject.otherPediatricsen_US
dc.subject.otherAngiotensin Converting Enzyme Inhibitorsen_US
dc.subject.otherMedicine & Public Healthen_US
dc.subject.otherFetopathyen_US
dc.titleInvited Review Recognition and management of angiotensin converting enzyme inhibitor fetopathyen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbsecondlevelPediatricsen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumPediatric Nephrology Service, University of Michigan Medical Center, Simpson Road East, Box 0297-L2602, 1521, Ann Arbor, MI, 48109-0297, USAen_US
dc.contributor.affiliationumPediatric Nephrology Service, University of Michigan Medical Center, Simpson Road East, Box 0297-L2602, 1521, Ann Arbor, MI, 48109-0297, USAen_US
dc.contributor.affiliationumPediatric Nephrology Service, University of Michigan Medical Center, Simpson Road East, Box 0297-L2602, 1521, Ann Arbor, MI, 48109-0297, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid7632538en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/47835/1/467_2005_Article_BF02254221.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF02254221en_US
dc.identifier.sourcePediatric Nephrologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record